Top

Published in:

01-04-2018 | Original Article

Serotonin transporter polymorphism, depressive symptoms, and emotional impulsivity among advanced breast cancer patients

Authors: Youngmee Kim, Charles S. Carver, Joachim F. Hallmayer, Jamie M. Zeitzer, Oxana Palesh, Eric Neri, Bita Nouriani, David Spiegel

Published in: Supportive Care in Cancer | Issue 4/2018

Abstract

Purpose

This study tested a theory linking a marker of low serotonergic function to both depression and impulsivity in a sample of advanced breast cancer patients, among whom elevated depressive symptoms and difficulty regulating emotions are commonly reported.

Methods

A total of 95 patients provided blood samples for serotonin transporter polymorphic region of the gene (5-HTTLPR) and completed questionnaires that measured depressive symptoms and emotional impulsivity.

Results

Structural equation modeling revealed that the s allele of 5-HTTLPR was related to greater depressive symptoms (β = .20, p < .042) but only marginally to greater emotional impulsivity (β = .19, p < .068). Depressive symptoms and emotional impulsivity were positively related (β = .33, p < .003). Further tests explored possible mediation from genotype to one psychological variable via the other. Results suggest that depressive symptoms, particularly perceived interpersonal rejection, may be a pathway linking genotype to emotional impulsivity.

Conclusions

Findings provide the first evidence that low serotonergic function contributes to both depression and impulsivity within a clinically meaningful sample. Furthermore, the link of s allele of 5-HTTLPR to emotional impulsivity was mediated by depressive symptoms, particularly perceptions of social rejection. Findings have implications for advanced breast cancer patients’ treatment decision.

Beitchman, J. H., Davidge, K. M., Kennedy, J. L., Atkinson, L., Lee, V., Shapiro, S., & Douglas L. (2003). The serotonin transporter gene in aggressive children with and without ADHD and nonaggressive matched controls. Annals of New York Academy of Science, 1008, 248–251

Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386–389CrossRefPubMed

Collier DA, Stöber G, Li T, Heils A, Catalano M, di Bella D, Arranz MJ, Murray RM, Vallada HP, Bengel D, Müller CR, Roberts GW, Smeraldi E, Kirov G, Sham P, Lesch KP (1996) A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1:453–460PubMed

Hoefgen B, Schulze TG, Ohlraun S, von Widdern O, Höfels S, Gross M, Heidmann V, Kovalenko S, Eckermann A, Kölsch H, Metten M, Zobel A, Becker T, Nöthen MM, Propping P, Heun R, Maier W, Rietschel M (2005) The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry 57:247–251CrossRefPubMed

Cools R, Blackwell A, Clark L, Menzies L, Cox S, Robbins TW (2005) Tryptophan depletion disrupts the motivational guidance of goal-directed behavior as a function of trait impulsivity. Neuropsychopharmacology 30:1362–1373CrossRefPubMed

Lyons-Ruth K, Holmes BM, Sasvari-Szekely M, Ronai Z, Nemoda Z, Pauls D (2007) Serotonin transporter polymorphism and borderline or antisocial traits among low-income young adults. Psychiatr Genet 17:339–343CrossRefPubMedPubMedCentral

Carver CS, Miller CJ (2006) Relations of serotonin function to personality: current views and a key methodological issue. Psychiatry Res 144:1–15CrossRefPubMed

Carver CS, Johnson SL, Joormann J (2008) Serotonergic function, two-mode models of self-regulation, and vulnerability to depression: what depression has in common with impulsive aggression. Psychol Bull 134:912–943CrossRefPubMedPubMedCentral

Depue RA, Spoont MR (1986) Conceptualizing a serotonin trait: a behavioral dimension of constraint. Ann N Y Acad Sci 487:47–62CrossRefPubMed

10.

Spoont MR (1992) Modulatory role of serotonin in neural information processing: implications for human psychopathology. Psychological Bulletin 112:330–350CrossRefPubMed

11.

Carver CS, Johnson SL, Joormann J (2013) Major depressive disorder and impulsive reactivity to emotion: toward a dual process view of depression. Br J Clin Psychol 52:285–299CrossRefPubMedPubMedCentral

12.

Carver CS, Johnson SL, Joormann J, Kim Y, Nam JY (2011) Serotonin transporter polymorphism interacts with childhood adversity to predict aspects of impulsivity. Psychol Sci 22:589–595CrossRefPubMed

13.

Stoltenberg SF, Christ CC, Highland KB (2012) Serotonin system gene polymorphisms are associated with impulsivity in a context dependent manner. Prog Neuro-Psychopharmacol Biol Psychiatry 39:182–191CrossRef

14.

Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE (2010) Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. American Journal of Psychiatry 167:502–527CrossRef

15.

Uher R, McGuffin P (2010) The moderation by the serotonin transporter gene of environmental adversity in the aetiology of depression: 2009 update. Molecular Psychiatry 15:18–22CrossRefPubMed

16.

Golden-Kreutz DM, Andersen BL (2004) Depressive symptoms after breast cancer surgery: relationships with global, cancer-related, and life event stress. Psycho-Oncology 13:211–220CrossRefPubMedPubMedCentral

17.

Mehnert A, Koch U (2007) Prevalence of acute and post-traumatic stress disorder and comorbid mental disorders in breast cancer patients during primary cancer care: a prospective study. Psycho-Oncology 16:181–188CrossRefPubMed

18.

Andersen BL, DeRubeis RJ, Berman BS, Gruman J, Champion VL, Massie MJ, Holland JC, Patridge AH, Bak K, Somerfield MR, Rowland JH (2014) Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 32:1605–1619CrossRefPubMedPubMedCentral

19.

Walker J, Holm-Hansen C, Martin P, Sawhney A, Thekkumpurath P, Beals C, Symeonides S, Wall L, Murray G, Sharpe M (2013) Prevalence of depression in adults with cancer: a systematic review. Ann Oncol 24:895–900CrossRefPubMed

20.

Holland JC, Alici Y (2010) Management of distress in cancer patients. J Support Oncol 8:4–12PubMed

21.

Warren M (2010) Uncertainty, lack of control and emotional functioning in women with metastatic breast cancer: a review and secondary analysis of the literature using the critical appraisal technique. Eur J Cancer Care 19:564–574CrossRef

22.

Giege-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D (2011) Decreased in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol 29:413–420CrossRef

23.

Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johnsen C, Meader N (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160–174CrossRefPubMed

24.

Aldridge-Gerry A, Zeitzer JM, Palesh OG, Jo B, Nouriani B, Neri E, Spiegel D (2013) Psychosocial correlates of sleep quality and architecture in women with metastatic breast cancer. Sleep Med 14:1178–1186CrossRefPubMed

25.

Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, Lesch KP (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66:2621–2624CrossRefPubMed

26.

Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401CrossRef

27.

Gratz KL, Roemer L (2004) Multidimensional assessment of emotion regulation and dysregulation: development, factor structure, and initial validation of the difficulties in emotion regulation scale. J Psychopathol Behav Assess 26:41–54CrossRef

28.

AMOS 21.0. (2012). SPSS Amos users’ guide, Version 21.0. IBM

29.

Bollen KA (1989) Structural equations with latent variables. Wiley, New YorkCrossRef

30.

Hu L, Bentler PM (1999) Cutoff criteria for fit indices in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model 6:1–55CrossRef

31.

Shafer A (2006) Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J Clin Psychol 62:123–146CrossRefPubMed

32.

Kissane D (2009) Beyond the psychotherapy and survival debate: the challenge of social disparity, depression and treatment adherence in psychosocial cancer care. Psycho-Oncology 18:1–5CrossRefPubMed

33.

Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Research & Treatment 99:215–220CrossRef

34.

Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20:431–436CrossRefPubMed

35.

DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101–2107CrossRefPubMed

36.

Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL (2014) Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA 312:902–914CrossRefPubMedPubMedCentral

37.

Connolly T, Reb J (2005) Regret in cancer-related decisions. Health Psychol 24:S29–S34CrossRefPubMed

38.

Hack TF, Degner LF, Watson P, Sinha L (2006) Do patients benefit from participation in medical decision making? Longitudinal follow-up of women with breast cancer. Psycho-Oncology 15:9–19CrossRefPubMed

39.

Lantz PM, Janz NK, Fagerlin A, Schwartz K, Liu L, Lakhani I, Salem B, Katz SJ (2005) Satisfaction with surgery outcomes and the decision process in a population-based sample of women with breast cancer. Health Serv Res 40:745–768CrossRefPubMedPubMedCentral

40.

Sheehan J, Sherman KA, Lam T, Boyages J (2007) Association of information satisfaction, psychological distress and monitoring coping style with post-decision regret following breast reconstruction. Psycho-Oncology 16:342–351CrossRefPubMed

41.

Hilner BE, Smith TJ (1991) Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer—a decision-analysis model. N Engl J Med 324:160–168CrossRef

42.

Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, Albain KS (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671–1676CrossRefPubMed

43.

Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Landon RM, Blum D, Ubel PA, Schnipper LE (2009) American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 27:3868–3874CrossRefPubMed

44.

Smith TJ, Hillner BE (2011) Bending the cost curve in cancer care. N Engl J Med 364:2060–2065CrossRefPubMedPubMedCentral

45.

Spiegel D, Riba MB (2015) Managing anxiety and depression during treatment. Breast J 21:97–103CrossRefPubMed

Title: Serotonin transporter polymorphism, depressive symptoms, and emotional impulsivity among advanced breast cancer patients
Authors: Youngmee Kim
Charles S. Carver
Joachim F. Hallmayer
Jamie M. Zeitzer
Oxana Palesh
Eric Neri
Bita Nouriani
David Spiegel
Publication date: 01-04-2018
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 4/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3940-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2018

Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma

The relationship between child and caregiver sleep in acute lymphoblastic leukemia maintenance

Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer

A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies

Unpredictable episodic breathlessness in patients with advanced chronic obstructive pulmonary disease and lung cancer: a qualitative study

Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer